Indications Contra-Indications
Known castrate-resistant prostate cancer with painful bone metastasis
Metastatic disease refractory to hormone therapy
Severe pain poorly controlled with conventional narcotics
Not a candidate for local or wide field radiotherapy
Positive correlation between pain sites and osteoblastic lesions on bone scan
Painful sites of disease on both sides of the diaphragm
No chemotherapy or large field radiation in the past 4-12 weeks
Urinary catheter placed for incontinence
Life expectancy more than 4 weeks
Signed informed consent
Adequate bone marrow reserve
• Hemoglobin>9.0 mg/dl
• Absolute WBC >3500 /dl
• Absolute neutrophil >1500/dl
• Platelets >1,00,000/dl
Glomerular filtration rate >50 Ml/min; urea <12 mmol/L; creatinine <200 mmol/L
Absolutepregnancy, continuing breast feeding.

History of hypersenstitivty to EDTMP or similar phosphonate compounds

Relativemyelosuppressionchronic renal failure or deterioration of renal function (urea >12mmol/l; creatinine >150mmol/l; GFR <30 mL/min)

urinary incontinence

acute or chronic spinal cord compression and/or metastases at the base of the skull
Table 3: Criteria for patient selection for bone-seeking radionuclide therapy.